Compare Crispr Therapeutics AG (CRSP) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Logitech International SA — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Logitech International SA trades at $100.72 (market cap $14.53B). The key difference: Logitech International SA is far larger — about 2.9× Crispr Therapeutics AG's market cap, and Logitech International SA pays a 1.69% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LOGI | |
|---|---|---|
Market Cap | $4.97B | $14.53B |
Sector | Health | Technology |
52-Week High | $76.78 | $126.69 |
52-Week Low | $44.34 | $85.84 |
Enterprise Value | $3.32B | $12.88B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Logitech (LOGI) trades at $102.22, up 0.26% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a net margin of 14.69% and ROE of 32.78%, while recent quarters show consistent earnings beats. New product launches and a partnership with Call of Duty: Modern Warfare 4 highlight ongoing growth initiatives. Cash flow trends remain positive with 2026 operating cash flow projected at $1.0 billion.
Outlook is cautiously optimistic given mixed analyst ratings but solid fundamentals. Upside exists to the $113 consensus target, though competitive pressures and reliance on consumer spending pose risks. The stock offers value if execution on B2B and AI products drives margin expansion as anticipated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
